EC
EPIX

EntryPoint Capital’s ESSA Pharma EPIX Stock Holding History

EntryPoint Capital’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,420
Closed -$37.5K – 1527
2024
Q1 		$37.5K Buy
+4,420
New +$38.6K 0.03% 885

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EntryPoint Capital's EPIX Position: Q2 2024 in Review

EntryPoint Capital sold out of ESSA Pharma (EPIX) in Q2 2024, closing a stake of 4,420 shares — an estimated $37.5K sold.

EntryPoint Capital first reported a position in EPIX in Q1 2024 and held it in 1 quarter. The position peaked at $37.5K in Q1 2024. 31 funds tracked by Wall St. Rank hold EPIX as of Q2 2024.

  • EntryPoint Capital reported no remaining ESSA Pharma position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 4,420 ESSA Pharma shares in Q2 2024, an estimated $37.5K.
  • EntryPoint Capital first reported a position in ESSA Pharma in Q1 2024 and held it in 1 quarter.
  • EntryPoint Capital's ESSA Pharma position peaked at $37.5K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.